Klaria submits cannabinoid formulation patent application following significant progress
Klaria announces the completion and filing of a patent application for a unique cannabinoid formulation. It is designed to deliver a specified dose to the bloodstream in a rapid, simple and reproducible manner via the company’s stamp-sized oral mucosal films. Klaria sees significant potential in a number of areas.Initially, Klaria is focusing on developing a pharmaceutical pain relief treatment, an application area where the company’s cannabinoid formulation offers great advantages compared to the treatments available on the market today. Klaria has made significant progress within